scholarly journals Clinicopathologic characteristics, survival, and treatments for gastric adenosquamous carcinoma: a population-based study

2020 ◽  
Vol 27 (6) ◽  
Author(s):  
H.S. Li ◽  
M.Y. Zhang ◽  
K. Cheng ◽  
Y. Chen ◽  
Y.W. Zhou ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Adenosquamous Carcinoma ◽  
Advanced Disease ◽  
Population Based ◽  
Tumour Invasion ◽  
Chemotherapy Treatment ◽  
Curative Surgery ◽  
Clinicopathologic Characteristics ◽  
Population Based Study ◽  
Significant Difference

Background Gastric adenosquamous carcinoma (gasc) is a rare entity with distinctive characteristics that are not fully understood. In the present study, we evaluated the characteristics of this rare disease. Methods The U.S. Surveillance, Epidemiology, and End Results program database was searched to determine the clinicopathologic features, prognostic factors, and treatments for 246 patients with gasc and 42,735 patients with gastric adenocarcinoma (gac). Results Relative to gac, gasc is associated with higher proportions of cardia involvement, high-grade tumours, deep tumour invasion, metastatic lymph nodes, and chemotherapy treatment. In patients who underwent potentially curative surgery (pcs), gasc was associated with a higher proportion of radiotherapy use and poorer overall survival (p < 0.001), although no significant difference (p = 0.802) was observed after propensity score matching (psm). Multi­variate analysis after psm revealed that the independent prognostic factors for gasc were TNM stage [hazard ratio (hr): 1.512; p = 0.021] and regional nodes examined (hr: 0.588; p = 0.02). In patients with advanced disease, no significant difference in survival between gasc and gac was observed (p = 0.212), although survival was significantly poorer for gasc after psm (p = 0.019). Multivariate analysis after psm revealed that the independent prognostic factors for gasc were invasion depth (hr: 1.303; p = 0.036) and chemotherapy (hr: 0.444; p < 0.001). Conclusions Relative to gac, gasc was associated with more aggressive features, although survival outcomes were similar after pcs. Chemotherapy remains a mainstay of treatment for patients with advanced gasc, but its role remains unclear for patients who are undergoing pcs.

scholarly journals Head & neck acinar cell carcinoma: a population-based study using the seer registry

2020 ◽  
Author(s):  
Feiluore Yibulayin ◽  
Lei Feng ◽  
Meng Wang ◽  
Meng-meng Lu ◽  
Yuan Luo ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Population Based ◽  
Clinicopathologic Characteristics ◽  
Population Based Study ◽  
Ajcc Stage ◽  
Significant Difference ◽  
Grade Iii

Abstract Background: to explore the clinicopathologic characteristics, treatment and prognostic factors of head and neck acinar cell carcinoma (HNACC) comprehensively. Methods: A population-based study was conducted using data from the Surveillance, Epidemiology, and End Results database (1975- 2016). Overall survival (OS) and HNACC-specific survival of patients with different clinicopathologic variables were compared using the Kaplan-Meier method and Cox multivariate regression. Results: A total of 2624 primary HNACC cases (1052 males, 1572 females) were identified. There was a significant difference in gender distribution. Among the total cohort, 2416 cases originated from salivary glands, including 2325 parotid gland ACC cases. Regardless of confounding factors, the 10-year and 20-year disease-specific survival (DSS) was 93.6% and 90%, respectively. Surgery was favourably associated with better DSS and OS [HR = 0.13, P = 0.0092 and HR = 0.23, P = 0.0203]. Gender was the only demographic independent prognostic factor for both DSS and OS [male vs female, HR = 3.3, P = 0.0028 for DSS; HR = 2.44, P = 0.0376 for OS]. Higher pathological grade was adversely associated with DSS and OS [Grade II, HR= 4.03, P = 0.0444; Grade III + IV, HR = 35.64, P = 0.0000 for DSS; Grade III + IV, HR = 4.49, P = 0.0000 for OS, Grade I as reference]. In addition, TNM/AJCC stage was commonly associated with prognosis. Conclusion: Surgery was the only favourable prognostic indicator for both DSS and OS. Gender, age, pathological differentiation and TNM/AJCC stage were independent prognostic factors for survival.

scholarly journals Head & Neck Acinar Cell Carcinoma: A Population-Based Study Using the Seer Registry

2020 ◽  
Author(s):  
Feiluore Yibulayin ◽  
Meng Wang ◽  
Meng-meng Lu ◽  
Yuan Luo ◽  
Hui Liu ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Population Based ◽  
Clinicopathologic Characteristics ◽  
Population Based Study ◽  
Ajcc Stage ◽  
Significant Difference ◽  
Grade Iii

Abstract Background:to explorethe clinicopathologic characteristics, treatment and prognostic factors of head and neck acinar cell carcinoma (HNACC) comprehensively.Methods:A population-based study was conductedusing data from the Surveillance, Epidemiology, and End Results database (1975- 2016). Overall survival (OS) and HNACC-specific survival of patients with different clinicopathologic variables were compared using the Kaplan-Meier method and Cox multivariate regression.Results:A total of 2624 primary HNACC cases (1052 males, 1572 females) were identified. There was a significant difference in gender distribution. Among the total cohort, 2416 cases originated from salivary glands, including 2325 parotid gland ACC cases. Regardless of confounding factors, the 10-year and 20-year disease-specific survival (DSS) was 93.6% and 90%, respectively. Surgery was favourably associated with better DSS and OS [HR= 0.13, P = 0.0092 andHR = 0.23, P = 0.0203]. Gender was the only demographic independent prognostic factor for both DSS and OS [male vs female, HR = 3.3, P = 0.0028 for DSS; HR = 2.44, P = 0.0376 for OS]. Higher pathological grade was adversely associated with DSS and OS [Grade II, HR= 4.03, P = 0.0444; Grade III + IV, HR = 35.64, P = 0.0000 for DSS; Grade III + IV, HR = 4.49, P = 0.0000 for OS, Grade I as reference]. In addition, TNM/AJCC stage was commonly associated with prognosis.Conclusion:Surgerywasthe only favourable prognostic indicator for both DSS and OS. Gender, age, pathological differentiation and TNM/AJCC stage were independent prognostic factors for survival.

scholarly journals Adenosquamous carcinoma of the breast: a population-based study

Breast Cancer ◽  
2021 ◽  
Author(s):  
Cheng Xu ◽  
Zhangyuan Gu ◽  
Juan Liu ◽  
Xiaoyan Lin ◽  
Cheng Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptors ◽  
Adenosquamous Carcinoma ◽  
Histological Grade ◽  
Population Based ◽  
Clinicopathological Characteristics ◽  
Breast Cancer Patients ◽  
Duct Carcinoma ◽  
Population Based Study ◽  
Significant Difference

Abstract Background To summarize the clinicopathological characteristics, prognosis, and management of breast adenosquamous carcinoma (ASC). Methods A population-based study was performed using retrospectively extracted data from the Surveillance, Epidemiology, and End Results database for breast cancer patients with histological diagnoses of ASC, infiltrating duct carcinoma (IDC) and squamous cell carcinoma (SCC) from 2004 to 2016. Results ASC presented similar tumor size but low histological grade and less lymph node metastasis compared to IDC. ASC expressed less positive rate of hormone receptors and barely HER2, which was similar with SCC. ASC patients underwent the similar surgical and systematic treatment as IDC, only with less radiotherapy. Median follow-up data of 78 months showed that the prognosis of IDC patients was better than that of ASC patients (all p < 0.05 for BCSM and OS). ASC was not an independent prognosis factor of breast cancer. After propensity score matching (PSM), no significant difference in BCSM nor OS was observed between ASC and IDC groups. In HR-negative patients, the prognosis of ASC was similar with that of IDC, and both were superior to SCC. In HR-positive patients, the 5-year survival rate of ASC was 63.5%, which was far less than that in ASC of HR-negative (81.0%). Multivariate analysis showed that older age (age > 60) and advanced AJCC-stage were independent factors of poor prognosis in ASC, breast-conserving surgery was also ideally suited for ASC. Conclusions ASC has unique clinicopathological characteristics and prognosis. It is imperative to focus on a more precise and personalized treatment management of ASC patients.

scholarly journals Adenosquamous Carcinoma of the Breast: A Population-Based Study Using the SEER Database

2020 ◽  
Author(s):  
Zhangyuan Gu ◽  
Juan Liu ◽  
Xiaoyan Lin ◽  
Cheng Wang ◽  
Jiejing Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Adenosquamous Carcinoma ◽  
Population Based ◽  
Clinicopathological Characteristics ◽  
Breast Cancer Patients ◽  
Duct Carcinoma ◽  
Population Based Study ◽  
Significant Difference

Abstract Background: The present study is aimed at summarizing the clinicopathological characteristics, prognosis, and management of breast adenosquamous carcinoma (ASC). Methods: A population-based study was performed using retrospectively extracted data from the Surveillance, Epidemiology and End Results database for breast cancer patients with histological diagnoses of ASC, infiltrating duct carcinoma (IDC) and squamous cell carcinoma (SCC) from 2004 to 2016. End-points were overall survival (OS) and breast cancer-specific mortality (BCSM). Propensity Score Matching (PSM) was employed to minimize selection bias of baseline characteristics. Univariable and multivariable analyses were used for identifying valuable prognostic factors. Results: ASC presented similar tumor size but low histological grade and less lymph node metastasis compared to IDC. ASC expressed less positive rate of hormone receptors and barely HER2, which was similar with SCC (estrogen receptor (ER): ASC 27.74% and SCC 21.53%, progesterone receptor (PR): ASC 18.06% and SCC 12.85%, HER2: ASC 4.44% and SCC 7.53%). ASC patients underwent the same treatment as IDC (chemotherapy 36.99% vs. 41.86%, BCS 50.58% vs 52.83%, P >0.05), only with less radiotherapy (39.88% vs. 48.34%, P<0.05). Median follow-up data of 78 months showed that the prognosis of IDC patients was better than that of ASC patients (all P <0.05 for BCSM and OS). After adjustment for clinicopathological and therapeutic factors in Cox proportional hazards models, ASC was no longer an independent poor prognosis factor. In matched groups, no significant difference in BCSM nor OS was observed between ASC and IDC groups. In HR-negative patients, the prognosis of ASC was similar with that of IDC, and both were superior to SCC. In HR-positive patients, the five-year survival rate of ASC was only about 60%, which was far less than that in ASC of HR-negative, the poor prognosis of ASC was closer to that of SCC. Multivariate analysis showed that older age (age≥60) and advanced AJCC stage (III and IV) were independent factors of poor prognosis in ASC, breast-conserving surgery was also ideally suited for ASC. Conclusions: ASC has unique clinicopathological characteristics and prognosis. To improve the clinical and biological understanding of ASC can make breast cancer patients get more individualized treatment.

Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study

2018 ◽  
Vol 18 (1) ◽  
pp. e97-e105 ◽  
Author(s):  
Wei Chen ◽  
Ying Huang ◽  
Gary D. Lewis ◽  
Sean S. Szeja ◽  
Sandra S. Hatch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Treatment Outcomes ◽  
Stage Iv ◽  
Population Based ◽  
Population Based Study ◽  
Stage Iv Breast Cancer ◽  
Male Patients
Sign in / Sign up

Export Citation Format

Share Document